Table 2.
Targeted-NP-Based Therapeutics which Follow Active Targeting
| Trade name | NP Type | Company | Targeting Ligand | Disease | Payload | Current Status |
Clinical Trial No. |
|---|---|---|---|---|---|---|---|
| SGT-53 | Liposome | SynerGene Therapeutics, Inc. | Transferrin single-chain antibody fragment | Advanced solid tumors | Gene 53 | Phase Ib | NCT00470613 |
| MBP-426 | Liposome | Mebiopharm | Transferrin | Solid tumors and esophagus disorders | Oxaliplatin | Phase II | NCT00355888, NCT00964080 |
| SEL-068 | Polymeric | Selecta Biosciences | Small molecule | Smoking cessation vaccine | Nicotine antigen T-helper cell peptide, TLR agonist | Phase I | NCT01478893 |
| CALAA-01 | Polymeric | Calando | Human Transferrin | Solid tumors | siRNA | Phase Ib | NCT00689065 |
| BIND-014 | Polymeric | Bind Biosciences | PSMA peptide | Metastatic cancer | Docetaxel | Phase I | NCT01300533 |
| SGT-94 | Liposome | SynerGene Therapeutics, Inc | Anti-transferrin receptor single chain antibody fragment | Solid tumors | RB94 gene | Phase I | NCT01517464 |